Evidence map›Paper›PMID 34810225›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2021

Mouse Homologue of Human HLA-DO Does Not Preempt Autoimmunity but Controls Murine Gammaherpesvirus MHV68.

Jean Lee, Emily Cullum, Kyle Stoltz, Niklas Bachmann, Zoe Strong, Danielle D Millick, Lisa K Denzin, Anthony Chang, Vera Tarakanova, Alexander V Chervonsky and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jean LeeCommittee on Cancer Biology, the University of Chicago, Chicago, IL.
Emily CullumCommittee on Immunology, the University of Chicago, Chicago, IL.ORCID 0000-0002-6741-2574
Kyle StoltzDepartment of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI.
Niklas BachmannDepartment of Microbiology, the University of Chicago, Chicago, IL.ORCID 0000-0001-8169-1592
Zoe StrongDepartment of Pathology, the University of Chicago, Chicago, IL.ORCID 0000-0001-7168-0902
Danielle D MillickGraduate School of Biomedical Sciences, Rutgers University, Piscataway, NJ.ORCID 0000-0003-4916-3866
Lisa K DenzinGraduate School of Biomedical Sciences, Rutgers University, Piscataway, NJ.ORCID 0000-0002-0554-4547
Anthony ChangDepartment of Pathology, the University of Chicago, Chicago, IL.ORCID 0000-0002-6877-5510
Vera TarakanovaDepartment of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI.
Alexander V ChervonskyCommittee on Immunology, the University of Chicago, Chicago, IL; tgolovki@bsd.uchicago.edu achervon@bsd.uchicago.edu.
Tatyana GolovkinaCommittee on Immunology, the University of Chicago, Chicago, IL; tgolovki@bsd.uchicago.edu achervon@bsd.uchicago.edu.ORCID 0000-0002-2924-6747
University of Chicago · USMedical College of Wisconsin · USRutgers, The State University of New Jersey · US

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI CHIEN-MIN KAO · 1985 to 2026
$122.1M
Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
Host's and microbiota's contribution to sexual dimorphism of autoimmunityR01AI127411 · NIAID · UNIVERSITY OF CHICAGO · PI ALEXANDER V CHERVONSKY · 2017 to 2026
$5.4M
New retroviral restriction factorR01AI117535 · NIAID · UNIVERSITY OF CHICAGO · PI GOLOVKINA, TATYANA V · 2016 to 2020
$3.2M
New retroviral restriction factorR56AI117535 · NIAID · UNIVERSITY OF CHICAGO · PI GOLOVKINA, TATYANA V · 2021 to 2021
$776k
NCATS NIH HHS UL1 TR000430NCI NIH HHS P30 CA014599NIAID NIH HHS R01 AI117535NIAID NIH HHS R01 AI127411NIAID NIH HHS R56 AI117535
6 · The paper itself

Abstract

H2-O (human HLA-DO) is a relatively conserved nonclassical MHC class II (MHCII)-like molecule. H2-O interaction with human HLA-DM edits the repertoire of peptides presented to TCRs by MHCII. It was long hypothesized that human HLA-DM inhibition by H2-O provides protection from autoimmunity by preventing binding of the high-affinity self-peptides to MHCII. The available evidence supporting this hypothesis, however, was inconclusive. A possibility still remained that the effect of H2-O deficiency on autoimmunity could be better revealed by using H2-O-deficient mice that were already genetically predisposed to autoimmunity. In this study, we generated and used autoimmunity-prone mouse models for systemic lupus erythematosus and organ-specific autoimmunity (type 1 diabetes and multiple sclerosis) to definitively test whether H2-O prevents autoimmune pathology. Whereas our data failed to support any significance of H2-O in protection from autoimmunity, we found that it was critical for controlling a γ-herpesvirus, MHV68. Thus, we propose that H2-O editing of the MHCII peptide repertoire may have evolved as a safeguard against specific highly prevalent viral pathogens.

Indexed as

AutoimmunityHLA-D AntigensAnimalsAntigen PresentationHistocompatibility Antigens Class IIHumansMicePeptidesReceptors, Antigen, T-CellHistocompatibility Antigens Class IIHLA-D AntigensPeptidesReceptors, Antigen, T-Cell

Identifiers

PMID34810225
PMCPMC9124240
OpenAlexW3215692785

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.